The DOI matches its Crossref record; 534 of the 534 references it cites were found in a registry or an index.
Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV
Abstract
Dipeptidyl-peptidase IV/CD26 (DPP IV) is a cell-surface protease belonging to the prolyloligopeptidase family. It selectively removes the N-terminal dipeptide from peptides with proline or alanine in the second position. Apart from its catalytic activity, it interacts with several proteins, for instance, adenosine deaminase, the HIV gp120 protein, fibronectin, collagen, the chemokine receptor CXCR4, and the tyrosine phosphatase CD45. DPP IV is expressed on a specific set of T lymphocytes, where it is up-regulated after activation. It is also expressed in a variety of tissues, primarily on endothelial and epithelial cells. A soluble form is present in plasma and other body fluids. DPP IV has been proposed as a diagnostic or prognostic marker for various tumors, hematological malignancies, immunological, inflammatory, psychoneuroendocrine disorders, and viral infections. DPP IV truncates many bioactive peptides of medical importance. It plays a role in glucose homeostasis through proteolytic inactivation of the incretins. DPP IV inhibitors improve glucose tolerance and pancreatic islet cell function in animal models of type 2 diabetes and in diabetic patients. The role of DPP IV/ CD26 within the immune system is a combination of its exopeptidase activity and its interactions with different molecules. This enables DPP IV/CD26 to serve as a co-stimulatory molecule to influence T cell activity and to modulate chemotaxis. DPP IV is also implicated in HIV-1 entry, malignant transformation, and tumor invasion.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
On the size of the active site in proteases. I. Papain
Schechter, I., & Berger, A. (1967) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(67)80055-x · Cited by 5,204 · cited 20×
“(continued) ing SDF-1α and MDC.”
BackgroundInfluentialHIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor
Feng, Y., Broder, C. C., Kennedy, P. E., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5263.872 · Cited by 4,172
Zlotnik, A., & Yoshie, O. (2000) · Immunity · doi:10.1016/s1074-7613(00)80165-x · Cited by 3,859
Identification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., et al. (1996) · Nature · doi:10.1038/381667a0 · Cited by 3,174
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., & Lusso, P. (1995) · Science · doi:10.1126/science.270.5243.1811 · Cited by 2,869
Chemokines and leukocyte traffic
Baggiolini, M. (1998) · Nature · doi:10.1038/33340 · Cited by 2,709
CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1
Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5270.1955 · Cited by 2,706
Handbook of Proteolytic Enzymes
(2004) · Elsevier eBooks · doi:10.1016/c2009-0-03628-9 · Cited by 2,616
Research works printed but not linked: 51
- Martin RA, 1993, Extended DPP-IV substrate specificity? Biochim Biophys Acta, 1164, 252
- Heymann E, 1986, Biomed Biochim Acta, 45, 575
- Heiduschka P, 1989, Pharmazie, 44, 778
- Barth A, 1974, Acta Biol Med Ger, 32, 157
- Gonzalez-Gronow M, 2001, Biochem J, 355, 397, 10.1042/bj3550397 · doi:10.1042/bj3550397
- Kenny AJ, 1977, Acta Biol Med Ger, 36, 1575
- Sterchi E., 1981, Pediatr Res, 15, 884
- Büchsel R, 1986, Eur J Cell Biol, 40, 53
- Riemann D, 2001, Biochem J, 354, 47, 10.1042/bj3540047 · doi:10.1042/bj3540047
- Küllertz G, 1989, Z Med Lab Diagn, 30, 273
- Vanhoof G, 1992, Eur J Clin Chem Clin Biochem, 30, 333
- Buhling F, 1994, Nat Immun, 13, 270
- Munoz E, 1992, Immunology, 77, 43
- Vanham G, 1993, J Acquir Immune Defic Syndr, 6, 749
- Annunziato F, 1998, Eur Cytokine Netw, 9, 12
- Stefanovic V, 1993, Immunology, 80, 465
- Cuchacovich M, 2001, Clin Exp Rheumatol, 19, 673
- Kasahara Y, 1983, Jpn J Clin Chem, 12, 89
- Antczak C, 2001, J Biol Regul Homeost Agents, 15, 130
- Stange T, 2000, Eur J Histochem, 44, 157
- Ten Kate J, 1986, Anticancer Res, 6, 983
- Kajiyama H, 2002, Cancer Res, 62, 2753
- Verstovsek S, 2000, Oncology (Huntingt), 14, 17
- Schonermarck U, 2000, Clin Exp Rheumatol, 18, 457
- Muller A, 2000, J Pathol, 192, 113, 10.1002/1096-9896(2000)9999:9999<::aid-path656>3.0.co;2-m · doi:10.1002/1096-9896(2000)9999:9999<::aid-path656>3.0.co;2-m
- Strunk T, 2000, Ann Neurol, 47, 269, 10.1002/1531-8249(200002)47:2<269::aid-ana23>3.0.co;2-g · doi:10.1002/1531-8249(200002)47:2<269::aid-ana23>3.0.co;2-g
- Kähne T, 1999, Int J Mol Med, 4, 3
- Zukowska-Grojec Z, 1996, Am J Physiol, 270, H796
- Neuropeptide Zukowska-Grojec Z., 1997, Drug News Perspectives, 10, 587
- Pappas TN, 1985, Am J Physiol, 248, G118
- Zubrzycka M, 2000, Endocr Regul, 34, 195
- Ahmad S, 1992, J Pharmacol Exp Ther, 260, 1257
- Hartrodt B, 1982, Pharmazie, 37, 72
- Sherwood NM, 2000, Endocr Rev, 21, 619
- Dhanvantari S, 1996, Mol Endocrinol, 10, 342
- Cheeseman CI, 1996, Am J Physiol, 271, G477
- Krarup T, 1985, Am J Physiol, 249, E195
- Deacon CF, 2000, J Clin Endocrinol Metab, 85, 3575
- Kato I, 1994, Evidence for improved glucose tolerance and enhanced insulin secretion by VIP and PHM-27 in vivo. J Biol Chem, 269, 21223
- Karlsson S, 1998, Am J Physiol, 274, E124
- Rocca AS, 1999, Endocrinology, 140, 1687, 10.1210/endo.140.4.6643 · doi:10.1210/endo.140.4.6643 · Paper page
- Deacon CF, 1995, J Clin Endocrinol Metab, 80, 952
- Gutzwiller JP, 1999, Am J Physiol, 276, R1541
- Schön E, 1985, Biomed Biochim Acta, 44, K9
- Gines S, 2002, Biochem J, 361, 203, 10.1042/bj3610203 · doi:10.1042/bj3610203
- Luster AD, 1998, Proc Assoc Am Physicians, 110, 183
- Ho L, 2001, Clin Cancer Res, 7, 2031
- Albino AP, 1992, Oncogene, 7, 2315
- Fountain JW, 1990, Cancer Surv, 9, 645
- Fischer G, 1983, Pharmazie, 38, 249
- Tiruppathi C, 1993, Am J Physiol, 265, G81
Cited by
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,265
“Remarkably, unlike SARS-CoV, MERS-CoV has the ability to infect human dendritic cells [43] and macrophages [44] in vitro, thus helping the virus to disrupt the immune system.”
BackgroundMiddle East respiratory syndrome
Zumla, A., Hui, D. S., & Perlman, S. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60454-8 · Cited by 1,263
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03120-0 · Cited by 1,175
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Metadata
- Authors
- Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I.
- Affiliations
- University of Antwerp (BE)
- Corresponding author
- Lambeir, Anne-Marie
- Venue
- Critical Reviews in Clinical Laboratory Sciences
- Publisher
- Informa UK Limited
- Published
- 2003-01
- Volume
- 40
- Issue
- 3
- Pages
- 209-294
- ISSN
- 1040-8363 (ISSN-L)
- 1549-781X
- OpenAlex
- W2028849170
- Semantic Scholar
- 625ef9bd8453b270d6519409d5ef4ce3f17388ca
- Cited by
- 955
- References
- 529
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 53 · 2021: 62 · 2020: 80 · 2019: 50 · 2018: 43 · 2017: 44 · 2016: 57 · 2015: 49 · 2014: 43 · 2013: 50 · 2012: 40
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Reviews in Clinical Laboratory Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- dipeptidyl peptidase IV, CD26, T cells, DPP-4 inhibitors, type 2 diabetes, tumor markers, HIV-1 entry, CXCR4, CD45, T cell costimulation, chemotaxis, tumor invasion, glucose homeostasis
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Disease Models, Animal, Humans, Molecular Sequence Data, T-Lymphocytes, Biomarkers, Dipeptidyl Peptidase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV. https://app.cochat.ai/papers/10.1080/713609354
- The paper
- Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003). Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV. Critical Reviews in Clinical Laboratory Sciences. https://doi.org/10.1080/713609354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.